In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir
The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche'